Gemcitabine plus S-1 for metastatic pancreatic cancer

Hong Zhu, Cheng Yi, Yaqin Zhao, Hongfeng Gou, Hong Zhu, Cheng Yi, Yaqin Zhao, Hongfeng Gou

Abstract

To investigate the treatment effects of gemcitabine plus S-1 (GS) for metastatic pancreatic cancer in our institution.Data from 41 patients with metastatic pancreatic cancer treated with GS regimen in West China Hospital, Sichuan University were reviewed. The therapeutic efficacy and toxicity were evaluated. The influencing factors of progression-free survival (PFS) and overall survival (OS) were also explored.At the last follow-up, all patients had died. The objective response rate was 22.0% (9/41) and the disease control rate was 65.9% (27/41). The median PFS and OS times were 5.1 (range, 1.5-21) and 10.6 months (range, 1.5-40), respectively. The 0.5-, 1-, and 2-year OS rates were 65.9%, 41.5%, and 9.8%, respectively. In multivariate analysis, body mass index and carbohydrate antigen 19-9 change were the significant influencing factors of PFS, compared to tumor site and chemotherapy cycles for OS. The adverse effects were moderate and tolerable.The effects of GS for metastatic pancreatic cancer in our institution were good. The adverse effects were moderate and tolerable. However, further investigation in future prospective clinical studies is warranted.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Progression free survival of patients with different variables. A. whole group; B. BMI; C. CA19-9 change. CA19-9 = carbohydrate antigen 19-9.
Figure 2
Figure 2
Overall survival of patients with different variables. A. whole group; B. tumor sites; C. chemotherapy cycles.

References

    1. Ueno H, Okusaka T, Furuse J, et al. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 2011;41:953–8.
    1. Nakai Y, Isayama H, Sasaki T, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 2012;106:1934–9.
    1. Li Y, Sun J, Jiang Z, et al. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. J Chemother (Florence, Italy) 2015;27:227–34.
    1. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57:98–104.
    1. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol Off J Am Soc Clin Oncol 1997;15:2403–13.
    1. Nakamura K, Yamaguchi T, Ishihara T, et al. Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 2006;94:1575–9.
    1. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 2013;369:1691–703.
    1. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol Off J Am Soc Clin Oncol 2007;25:1960–6.
    1. van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol Off J Am Soc Clin Oncol 2000;18:2772–9.
    1. Sudo K, Nakamura K, Yamaguchi T. S-1 in the treatment of pancreatic cancer. World J Gastroenterol 2014;20:15110–8.
    1. Okusaka T, Funakoshi A, Furuse J, et al. A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 2008;61:615–21.
    1. Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol 2009;39:2–15.
    1. Yoshizawa J, Takizawa A, Takeuchi O, et al. Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer Chemother Pharmacol 2009;64:1211–9.
    1. Morimoto Y, Takeuchi O, Takizawa A, et al. Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines. Anti-Cancer Drugs 2012;23:505–14.
    1. Nakahira S, Nakamori S, Tsujie M, et al. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 2008;28:179–86.
    1. Ueno H, Okusaka T, Ikeda M, et al. A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 2005;69:421–7.
    1. Nakai Y, Isayama H, Sasaki T, et al. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 2009;77:300–3.
    1. Wu D, Zhu H, Tang H, et al. Clinical analysis of stereotactic body radiation therapy using extracranial gamma knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma. Radiat Oncol (Lond, Engl) 2011;6:84.
    1. Xu J, Zhu H, Zhao Y, et al. Factors associated with hepatic dysfunction in hepatitis B-positive patients with postgastrectomy adenocarcinoma. Oncol Lett 2012;4:471–6.
    1. Huang M, Zhu H, Liu T, et al. Comparison of external radiotherapy and percutaneous vertebroplasty for spinal metastasis. Asia Pac J Clin Oncol 2016;12:e201–208.
    1. Lau MK, Davila JA, Shaib YH. Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 2010;39:458–62.
    1. Sudo K, Ishihara T, Hirata N, et al. Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer. Cancer Chemother Pharmacol 2014;73:389–96.
    1. Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol Off J Am Soc Clin Oncol 2013;31:1640–8.
    1. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999;189:1–7.
    1. Ruess DA, Makowiec F, Chikhladze S, et al. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. BMC Surg 2015;15:123.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir